HC Wainwright Analysts Give Histogenics (HSGX) a $4.00 Price Target

Histogenics (NASDAQ:HSGX) has been assigned a $4.00 target price by analysts at HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 94.17% from the stock’s current price.

Other analysts have also recently issued reports about the company. Zacks Investment Research raised Histogenics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Thursday, September 7th. Canaccord Genuity reaffirmed a “buy” rating and set a $4.00 price objective on shares of Histogenics in a research report on Thursday, December 21st.

Shares of Histogenics (NASDAQ:HSGX) opened at $2.06 on Wednesday. The stock has a market capitalization of $49.10, a PE ratio of -1.49 and a beta of 1.43. Histogenics has a 1 year low of $1.45 and a 1 year high of $2.40.

Histogenics (NASDAQ:HSGX) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. research analysts anticipate that Histogenics will post -0.99 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://weekherald.com/2017/12/27/hc-wainwright-analysts-give-histogenics-hsgx-a-4-00-price-target-3.html.

About Histogenics

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply